Drugs / Combined diphtheria, tetanus, acellular pertussis vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00109330 | Nov 2002 → Apr 2004 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01267058 | Sep 1997 → Feb 1998 | diphtheria, pertussis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Combined diphtheria, tetanus, acellular pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00109330 ↗ |
| Known as | dTpa | “At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive combined reduced-antigen-content diphtheria-tetanus and acellular pertussis vaccine (dTpa)...” PMID 19095033 ↗ Dec 2008 |
| Modality | Vaccine | “Combined diphtheria, tetanus, acellular pertussis vaccine” NCT00109330 ↗ |
| Route | Intramuscular | “Intramuscular, single dose” NCT01267058 ↗ |